DK517986A - Dna-sekvenser, rekombinant-dna-molekyler og fremgangsmaade til fremstilling af mueller-inhiberende stof-lignende polypeptider - Google Patents

Dna-sekvenser, rekombinant-dna-molekyler og fremgangsmaade til fremstilling af mueller-inhiberende stof-lignende polypeptider

Info

Publication number
DK517986A
DK517986A DK517986A DK517986A DK517986A DK 517986 A DK517986 A DK 517986A DK 517986 A DK517986 A DK 517986A DK 517986 A DK517986 A DK 517986A DK 517986 A DK517986 A DK 517986A
Authority
DK
Denmark
Prior art keywords
polypeptides
mueller
inhibitor
procedures
preparation
Prior art date
Application number
DK517986A
Other languages
English (en)
Other versions
DK517986D0 (da
Inventor
Richard L Cate
Patricia K Donahoe
Original Assignee
Biogen Nv
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Nv, Gen Hospital Corp filed Critical Biogen Nv
Publication of DK517986D0 publication Critical patent/DK517986D0/da
Publication of DK517986A publication Critical patent/DK517986A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
DK517986A 1985-10-30 1986-10-29 Dna-sekvenser, rekombinant-dna-molekyler og fremgangsmaade til fremstilling af mueller-inhiberende stof-lignende polypeptider DK517986A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/792,880 US5047336A (en) 1985-10-30 1985-10-30 DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides

Publications (2)

Publication Number Publication Date
DK517986D0 DK517986D0 (da) 1986-10-29
DK517986A true DK517986A (da) 1987-05-01

Family

ID=25158349

Family Applications (1)

Application Number Title Priority Date Filing Date
DK517986A DK517986A (da) 1985-10-30 1986-10-29 Dna-sekvenser, rekombinant-dna-molekyler og fremgangsmaade til fremstilling af mueller-inhiberende stof-lignende polypeptider

Country Status (13)

Country Link
US (1) US5047336A (da)
EP (1) EP0221761B1 (da)
JP (2) JPH0720431B2 (da)
KR (1) KR870004143A (da)
AT (1) ATE119915T1 (da)
AU (1) AU606584B2 (da)
CA (1) CA1307753C (da)
DE (1) DE3650266T2 (da)
DK (1) DK517986A (da)
HU (1) HUT43627A (da)
IL (1) IL80451A0 (da)
PT (1) PT83655B (da)
ZA (1) ZA868251B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU622891B2 (en) * 1985-10-30 1992-04-30 Biogen, Inc. Cleaved dimers of mullerian inhibiting substance-like polypeptides
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides
US5427780A (en) * 1985-10-30 1995-06-27 Biogen, Inc. Composition comprising Mullerian inhibiting substance-like polypeptides
US5185441A (en) * 1988-08-26 1993-02-09 Biogen, Inc. Dna sequences, recombinant dna molecules and processes for producing pi-linked lymphocyte function associated antigen-3
US5661126A (en) * 1989-01-19 1997-08-26 The General Hospital Corporation Use of mullerian inhibiting substance for treating certain tumors and for modulating class I major histocompatibility antigen expression
US5349058A (en) * 1990-02-06 1994-09-20 E. R. Squibb & Sons, Inc. Nucleic acid encoding human mevalonate kinase
US5281520A (en) * 1990-09-12 1994-01-25 Zymogenetics, Inc. Method for producing acyloxyacyl hydrolase
US5310880A (en) * 1991-04-12 1994-05-10 The General Hospital Corporation Purification of Mullerian inhibiting substance
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
AU3920693A (en) * 1992-03-18 1993-10-21 General Hospital Corporation, The Four novel receptors of the TGF-beta receptor family
EE200100123A (et) * 1998-08-31 2002-06-17 Biogen, Incorporated CD2 siduva aine kasutamine ja mäluefektor-T-lümfotsüütide populatsioon
US20020119921A1 (en) * 1999-03-31 2002-08-29 Michael Streit Thrombospondin-2 and uses thereof
CA2384991A1 (en) * 1999-09-14 2001-03-22 The General Hospital Corporation Use of mullerian inhibiting substance for treating excess androgen states
WO2001055212A2 (en) 2000-01-27 2001-08-02 The General Hospital Corporation Delivery of therapeutic biological from implantable tissue matrices
US20030033637A1 (en) * 2001-06-05 2003-02-13 Croptech Corporation Gene expression and production of TGF-beta proteins including bioactive mullerian inhibiting substance from plants
WO2003009740A2 (en) * 2001-07-24 2003-02-06 Biogen Idec Ma Inc. Methods for treating or preventing sclerotic disorders using cd2-binding agents
EP1545604A4 (en) * 2002-08-23 2006-09-06 Gen Hospital Corp USE OF MISER (MULLERIAN INHIBITING SUBSTANCE) SUBSTANCE AND INTERFERON TO TREAT TUMORS
WO2005077018A2 (en) * 2004-02-06 2005-08-25 Astellas Us Llc Methods of treating skin disorders
MXPA06012744A (es) * 2004-05-04 2007-02-19 Genaissance Pharmaceutical Inc Marcadores de haplotipo y metodos para utilizarlos en la determinacion de la respuesta al tratamiento.
CA2565259A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
US20060162026A1 (en) * 2004-12-23 2006-07-20 Karen Oishi Expressing TGF-beta proteins in plant plastids
AU2005211556A1 (en) * 2005-03-24 2006-10-12 Otago Innovation Limited Method Of Modulation
CA2627336A1 (en) * 2005-10-26 2007-05-03 Otago Innovation Limited Method of modulation of mullerian inhibitory substance (mis) receptor for the treatment of neurodegenerative diseases.
WO2008116161A2 (en) 2007-03-22 2008-09-25 The General Hospital Corporation Pyrazoloanthrone and derivatives thereof for the treatment of cancer expressing 'mullerian inhibiting substance' type ii receptor (misrii) and of excess androgen states
US9289492B2 (en) 2007-07-17 2016-03-22 The General Hospital Corporation Collecting ovarian cancer stem cells from ovarian cancer cells
ITRM20120285A1 (it) 2012-06-18 2013-12-19 Alfonso Baldi Ormone anti-mulleriano.
PL2968470T3 (pl) * 2013-03-12 2021-05-31 The General Hospital Corporation Zmodyfikowane białka stanowiące substancję hamującą rozwój przewodów müllera (mis) i ich zastosowania do leczenia chorób
RU2616273C1 (ru) * 2016-04-21 2017-04-13 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Синтетическая ДНК, кодирующая антимюллеров гормон человека, содержащий ее экспрессионный вектор pTVK4pu/MISOPT и штамм клеток яичников китайского хомячка CHO-MIS - продуцент рекомбинантного антимюллерового гормона человека

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404188A (en) * 1981-07-29 1983-09-13 Massachusetts General Hospital Purified Mullerian Inhibiting Substance and method of purification
US4510131A (en) * 1981-07-29 1985-04-09 The General Hospital Corporation Purified Mullerian Inhibiting Substance and method of use
US4442205A (en) * 1981-09-22 1984-04-10 The United States Of America As Represented By The Department Of Health And Human Services Simian virus recombinant that directs the synthesis of hepatitis B surface antigen
US4487833A (en) * 1982-03-01 1984-12-11 The General Hospital Corporation Method of preparing hybridomas and of purifying immunogenic materials
US4740587A (en) * 1985-07-18 1988-04-26 The Salk Institute For Biological Studies Inhibin and method of purifying same
US5047336A (en) * 1985-10-30 1991-09-10 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing mullerian inhibiting substance-like polypeptides

Also Published As

Publication number Publication date
PT83655A (en) 1986-11-01
EP0221761A2 (en) 1987-05-13
ZA868251B (en) 1988-09-28
EP0221761A3 (en) 1988-10-12
AU606584B2 (en) 1991-02-14
HUT43627A (en) 1987-11-30
KR870004143A (ko) 1987-05-07
JP2541761B2 (ja) 1996-10-09
JPS62190084A (ja) 1987-08-20
US5047336A (en) 1991-09-10
PT83655B (en) 1988-11-29
IL80451A0 (en) 1987-01-30
AU6452186A (en) 1987-05-07
JPH0720431B2 (ja) 1995-03-08
DE3650266T2 (de) 1995-08-31
ATE119915T1 (de) 1995-04-15
EP0221761B1 (en) 1995-03-15
DK517986D0 (da) 1986-10-29
JPH06133793A (ja) 1994-05-17
CA1307753C (en) 1992-09-22
DE3650266D1 (de) 1995-04-20

Similar Documents

Publication Publication Date Title
DK517986D0 (da) Dna-sekvenser, rekombinant-dna-molekyler og fremgangsmaade til fremstilling af mueller-inhiberende stof-lignende polypeptider
AU2964489A (en) Dna sequences, recombinant dna molecules and processes for producing human immune interferon-like polypeptides
ZA822855B (en) Bacillus cloning vectors,recombinant dna molecules,bacillus hosts transformed with them and methods for expressing foreign dna sequences and producing polypeptides coded thereby
JPS55104887A (en) Rearranged dna molecule and method
DE69131580D1 (de) GDF-1 und UOG1 Proteine
MY101852A (en) Tumor necrosis factor, methods for its preparation, containing it, dna encoding it and assay method using such dna.
ES8400770A1 (es) Un metodo para producir una molecula de adn recombinante caracterizada por una secuencia de adn codificada de un coni- peptido semejante al, interferon humano.
EP0168214A3 (en) Tumor necrosis factor, methods for its preparation, compositions containing it, dna encoding it and assay method using such dna
DK368588D0 (da) Bindingsmolekyler med en enkelt plypeptidkaede
DK1265914T3 (da) WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme
ZA86217B (en) Dna sequences,recombinant dna molecules and processes for producing human lipocortin-like polypeptides
EP0091527A3 (en) Dna sequences, recombinant dna molecules and processes for producing human serum albumin-like polypeptides
DK54184A (da) Dna-sekvenser, rekombinations-dna-molekyler samt fremgangsmaader til fremstilling af human (interleukin) to-lignende polypeptider
DK572284A (da) Dna, der indkoder kanintnf, vektor med det deri indsatte dna, vaert transformeret med vektoren, kanintnfpolypeptid og fremgangsmaade til fremstilling af disse
FI863626A7 (fi) DNA-sekvenssejä, yhdistelmä-DNA -molekyylejä ja menetelmiä ihmisen lip okortiinin kaltaisia polypeptidejä.
DE3782549D1 (de) Neue polypeptide, ihre herstellung und ihre verwendung.
ES8800353A1 (es) Procedimiento de clonacion de factor humano viii-r.
BR0008917A (pt) Compostos
DK551786A (da) Rekombinant-dna-sekvens, der koder for aminosyresekvenser i et toksin, expressionssystem omfattende samme og vaertsceller transformeret hermed
ZA812189B (en) Dna sequences, recombinant dna molecules and processes for producing human fibroblast interferon-like polypeptides
NO871737D0 (no) Rekombinant virus, polypeptid samt dna molekyl med kodingssekvens for dette polypeptid.
DE3688974D1 (de) Expressionssysteme zur überproduktion gewünschter proteine.
GEP19970665B (en) Processes for producing human interferon-like polypeptides
IL65623A0 (en) Bacillus cloning vectors,recombinant dna molecules,bacillus hosts transformed with them and methods for expressing foreign dna sequences and producing poly-peptides coded thereby
MY102686A (en) Recombinant dna molecules and their method of production.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment